|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Virginia Commonwealth University |
|---|---|
| Information provided by: | Virginia Commonwealth University |
| ClinicalTrials.gov Identifier: | NCT00964678 |
Purpose
The purpose of this study is to determine whether carvedilol treatment of patients with pulmonary arterial hypertension and associated right heart failure is safe and results in an improved function of the right heart.
| Condition | Intervention | Phase |
|---|---|---|
|
Pulmonary Arterial Hypertension |
Drug: Carvedilol Drug: placebo |
Phase I Phase II |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension |
| Estimated Enrollment: | 24 |
| Study Start Date: | August 2009 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| carvedilol: Experimental |
Drug: Carvedilol
twice daily oral treatment in escalating dose
|
| Placebo: Placebo Comparator |
Drug: placebo
twice daily oral treatment in escalating dose
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Virginia | |
| Virginia Commonwealth University | Recruiting |
| Richmond, Virginia, United States, 23298 | |
| Contact: Herman Bogaard, MD, PhD 804-628-3334 hjbogaard@vcu.edu | |
| Principal Investigator: Herman J Bogaard, MD, PhD | |
| Principal Investigator: | Herman J. Bogaard, M.D, Ph.D. | Virginia Commonwealth University |
More Information
| Responsible Party: | Virginia Commonwealth University ( Herman Bogaard, Assistant Professor of Medicine ) |
| Study ID Numbers: | HM12120 |
| Study First Received: | August 24, 2009 |
| Last Updated: | August 24, 2009 |
| ClinicalTrials.gov Identifier: | NCT00964678 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Vasodilator Agents Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Vascular Diseases Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Respiratory Tract Diseases Hypertension, Pulmonary Therapeutic Uses Lung Diseases Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Hypertension Carvedilol |